1Elite School of Optometry, Sankara Nethralaya, Chennai, Tamil Nadu, India.
2Shri Bhagwan Mahavir Department of Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.
3Department of Preventive Ophthalmology (Epidemiology and Biostatistics), Sankara Nethralaya, Chennai, Tamil Nadu, India.
Copyright © 2011 The Korean Society for Preventive Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors have no conflicts of interest with the material presented in this paper.
This article is available at http://jpmph.org/.
Study name | Country | Publication year | Ethnicity | Gender | Age range (y) | Age (mean SD) (y) | Sample (n) | IOP measurement technique | IOP (mean SD) (mmHg) |
---|---|---|---|---|---|---|---|---|---|
Bankes JL [14] | England | 1967 | Mixed | Both | ≥40 | NA | 212 | GAT | 16.69 ± 3.32 |
Bouzas AG, et al [15] | New England | 1971 | Mixed | Both | 51 - 68 | NA | 56 | GAT | 15.19 ± 3.15 |
Williams B, et al [16] | England | 1980 | Mixed | Both | 25 - 70 | 53.36±13.3 | 14 | Perkins handheld | 18.9 ± 2.25 |
Wisconsin epidemiologic study [17] | USA | 1984 | Mixed | Both | 0 to >75 | NA | 2990 | GAT | 16.3 ± 4.12 |
Arora VK, et al [7] | India | 1989 | Asian | Males | NA | NA | 46 | Schiotz | 19.26 |
al-Sereiti MR, et al [13] | England | 1991 | Mixed | Both | NA | .0040±15 | 38 | Non-contact Pneumotonometer | 15.5±3.9 |
Beaver dam eye study [3] | USA | 1992 | Mixed | Both | 43 - 84 | NA | 438 | GAT | 16.05 ± 3.8 |
Baltimore eye survey [9] | USA | 1995 | Mixed | Both | ≥40 | NA | 714 | GAT | 17.9 ± 0.24 |
Rotterdam study [18] | Netherland | 1996 | White | Both | ≥ 55 | 55 - 94 | 256 | GAT | 14.86 ± 2.91 |
Barbados eye study [2] | West Indies | 1997 | Mixed | Both | 40 - 84 | 58 | 17 | GAT | 18.6 ± 3.7 |
Barbados incidence study of eye diseases [8] | West Indies | 2003 | Mixed | Both | 40 - 84 | 057.5 ± 11.5 | 559 | GAT | 21.5 ± 4.7 |
Oshitari T [12] | Japan | 2007 | Japanese | Both | NA | 60.86 ± 10.76 | 190 | GAT | 16.0 ± 2.5 |
Los Angeles Latino eye study [11] | USA | 2008 | Mexicans | Both | ≥ 40 | NA | 1416 | GAT | 15.2 ± 3.3 |
Beijing eye study [10] | China | 2009 | Chinese | Both | 45 - 89 | 060.4 ± 10 | 381 | Non-contact Pneumotonometer | 16.14 ± 2.96 |
Present study | India | 2010 | Asian | Both | ≥ 40 | 56.32 ± 10.02 | 1414 | GAT | 14.8 ± 2.9 |
STDR: sight threatening diabetic retinopathy (severe Nonproliferative diabetic retinopathy, proliferative diabetic retinopathy and clinically significant macular edema), CSME: clinically significant macular edema, HbA1c: glycosylated hemoglobin, BP: blood pressure, CCT: central corneal thickness, BMI: body mass index, FBS: fasting blood sugar.
CCT: central corneal thickness, CI: confidence interval, SN-DREAMS 1: Sankara Nethralaya-diabetic Retinopathy Epidemiology and Molecular Genetic Study.
The variables adjusted in multiple regression analysis are age, duration of diabetes, weight, height, systolic and diastolic blood pressure, pulse, central corneal thickness, axial length, total serum cholesterol, serum high density lipoproteins, serum triglycerides, glycosylated hemoglobin and fasting blood sugar.
Study name | Country | Publication year | Ethnicity | Gender | Age range (y) | Age (mean SD) (y) | Sample (n) | IOP measurement technique | IOP (mean SD) (mmHg) |
---|---|---|---|---|---|---|---|---|---|
Bankes JL [14] | England | 1967 | Mixed | Both | ≥40 | NA | 212 | GAT | 16.69 ± 3.32 |
Bouzas AG, et al [15] | New England | 1971 | Mixed | Both | 51 - 68 | NA | 56 | GAT | 15.19 ± 3.15 |
Williams B, et al [16] | England | 1980 | Mixed | Both | 25 - 70 | 53.36±13.3 | 14 | Perkins handheld | 18.9 ± 2.25 |
Wisconsin epidemiologic study [17] | USA | 1984 | Mixed | Both | 0 to >75 | NA | 2990 | GAT | 16.3 ± 4.12 |
Arora VK, et al [7] | India | 1989 | Asian | Males | NA | NA | 46 | Schiotz | 19.26 |
al-Sereiti MR, et al [13] | England | 1991 | Mixed | Both | NA | .0040±15 | 38 | Non-contact Pneumotonometer | 15.5±3.9 |
Beaver dam eye study [3] | USA | 1992 | Mixed | Both | 43 - 84 | NA | 438 | GAT | 16.05 ± 3.8 |
Baltimore eye survey [9] | USA | 1995 | Mixed | Both | ≥40 | NA | 714 | GAT | 17.9 ± 0.24 |
Rotterdam study [18] | Netherland | 1996 | White | Both | ≥ 55 | 55 - 94 | 256 | GAT | 14.86 ± 2.91 |
Barbados eye study [2] | West Indies | 1997 | Mixed | Both | 40 - 84 | 58 | 17 | GAT | 18.6 ± 3.7 |
Barbados incidence study of eye diseases [8] | West Indies | 2003 | Mixed | Both | 40 - 84 | 057.5 ± 11.5 | 559 | GAT | 21.5 ± 4.7 |
Oshitari T [12] | Japan | 2007 | Japanese | Both | NA | 60.86 ± 10.76 | 190 | GAT | 16.0 ± 2.5 |
Los Angeles Latino eye study [11] | USA | 2008 | Mexicans | Both | ≥ 40 | NA | 1416 | GAT | 15.2 ± 3.3 |
Beijing eye study [10] | China | 2009 | Chinese | Both | 45 - 89 | 060.4 ± 10 | 381 | Non-contact Pneumotonometer | 16.14 ± 2.96 |
Present study | India | 2010 | Asian | Both | ≥ 40 | 56.32 ± 10.02 | 1414 | GAT | 14.8 ± 2.9 |
Risk factors | Over all (n=1377) |
Men (n=731) |
Women (n=646) |
||||||
---|---|---|---|---|---|---|---|---|---|
n | IOP (mmHg) | p | n | IOP (mmHg) | p | n | IOP (mmHg) | p | |
Mean IOP | 14.8 ± 2.9 | 14.6 ± 2.9 | 15.0 ± 2.8 | 0.005 | |||||
Demography | |||||||||
Age (y) | |||||||||
40 - 49 | 385 | 14.7 ± 2.7 | 0.69 | 210 | 14.4 ± 2.6 | 0.59 | 175 | 15.1 ± 2.8 | 0.94 |
50 - 59 | 494 | 14.9 ± 2.9 | 245 | 14.8 ± 3.1 | 249 | 15.1 ± 2.8 | |||
60 - 69 | 342 | 14.7 ± 2.9 | 178 | 14.6 ± 3.0 | 164 | 14.9 ± 2.9 | |||
70 + | 156 | 14.7 ± 2.9 | 98 | 14.6 ± 3.1 | 58 | 15.0 ± 2.6 | |||
Duration of diabetes (y) | |||||||||
< 5 | 799 | 14.8 ± 2.8 | 0.51 | 403 | 14.7 ± 2.9 | 0.21 | 396 | 14.9 ± 2.7 | 0.49 |
≥ 5 | 578 | 14.7 ± 2.9 | 328 | 14.4 ± 2.9 | 250 | 15.1 ± 2.9 | |||
Nuclear cataract | |||||||||
Absent | 1011 | 14.8 ± 0.438 | 0.44 | 550 | 14.6 ± 2.9 | 0.57 | 461 | 15.1 ± 2.8 | 0.69 |
Present | 187 | 15.0 ± 0.439 | 93 | 14.8 ± 3.0 | 94 | 15.2 ± 2.1 | |||
Alcohol history | |||||||||
Absent | 1074 | 14.9 ± 2.9 | 0.002 | 428 | 14.8 ± 2.9 | 0.06 | 646 | 15.0 ± 2.8 | - |
Present | 303 | 14.4 ± 2.9 | 303 | 14.4 ± 2.9 | 0 | - | |||
Refractive error | |||||||||
Absent | 511 | 14.8 ± 2.9 | 0.67 | 287 | 14.5 ± 3.0 | 0.64 | 224 | 15.0 ± 2.7 | 0.93 |
Present | 866 | 14.8 ± 2.9 | 444 | 14.6 ± 2.9 | 422 | 15.0 ± 2.8 | |||
Family history of glaucoma | |||||||||
Absent | 1371 | 14.8 ± 2.9 | 0.92 | 727 | 14.6 ± 2.9 | 0.50 | 224 | 15.0 ± 2.8 | 0.39 |
Present | 6 | 14.5 ± 2.8 | 4 | 13.5 ± 3.0 | 422 | 16.5 ± 0.71 | |||
Smoking status | |||||||||
Non smoker | 1106 | 14.3 ± 2.9 | 0.001 | 460 | 14.3 ± 2.9 | 0.021 | 646 | 15.0 ± 2.8 | - |
Smoker | 271 | 14.9 ± 2.9 | 271 | 14.8 ± 2.9 | 0 | - | |||
Insulin | |||||||||
Non user of insulin | 1310 | 14.8 ± 2.9 | 0.46 | 698 | 14.6 ± 2.9 | 0.42 | 612 | 15.0 ± 2.8 | 0.87 |
User of insulin | 67 | 15.1 ± 3.1 | 33 | 15.0 ± 3.3 | 34 | 15.1 ± 3.0 | |||
Anthropometry | |||||||||
BMI | |||||||||
Lean | 87 | 14.2 ± 2.9 | 0.19 | 66 | 14.2 ± 2.9 | 0.50 | 21 | 14.1 ± 3.1 | 0.38 |
Normal | 522 | 14.8 ± 3.0 | 365 | 14.7 ± 3.1 | 157 | 14.9 ± 2.9 | |||
Overweight | 562 | 14.9 ± 2.7 | 258 | 14.5 ± 2.8 | 304 | 15.2 ± 2.7 | |||
Obese | 206 | 14.9 ± 2.9 | 42 | 14.6 ± 2.8 | 164 | 14.9 ± 2.9 | |||
Height (cm) | |||||||||
≤ 156 | 586 | 15.0 ± 2.7 | 0.007 | 652 | 14.6 ± 2.9 | 0.95 | 619 | 15.1 ± 2.8 | 0.06 |
> 156 | 791 | 14.6 ± 2.9 | 79 | 14.6 ± 2.8 | 27 | 14.0 ± 3.0 | |||
Weight (kg) | |||||||||
< 57.5 | 410 | 14.7 ± 2.9 | 0.50 | 208 | 14.7 ± 3.1 | 0.08 | 163 | 14.8 ± 2.8 | 0.26 |
≥ 57.5 | 967 | 14.8 ± 2.9 | 523 | 14.6 ± 2.9 | 483 | 15.1 ± 2.8 | |||
Axial length (mm) | |||||||||
< 22.6 | 565 | 14.7 ± 2.9 | 0.25 | 257 | 14.3 ± 2.9 | 0.03 | 308 | 15.0 ± 2.7 | 0.97 |
≥ 22.6 | 786 | 14.9 ± 2.9 | 465 | 14.8 ± 2.9 | 321 | 15.1 ± 2.9 | |||
Hypertension | |||||||||
No | 499 | 14.6 ± 2.9 | 0.03 | 300 | 14.4 ± 2.9 | 0.10 | 199 | 14.9 ± 2.8 | 0.33 |
Yes | 878 | 14.9 ± 2.9 | 431 | 14.7 ± 2.9 | 447 | 15.1 ± 2.8 | |||
Systolic BP (mmHg) | |||||||||
< 130 | 401 | 14.4 ± 2.9 | 0.001 | 242 | 14.1 ± 2.8 | 0.003 | 159 | 14.8 ± 2.9 | 0.21 |
≥ 130 | 976 | 14.9 ± 2.9 | 489 | 14.8 ± 2.9 | 487 | 15.1 ± 2.8 | |||
Diastolic BP (mmHg) | |||||||||
< 80 | 429 | 14.7 ± 2.9 | 0.27 | 241 | 14.4 ± 2.9 | 0.17 | 188 | 15.0 ± 2.8 | 0.94 |
≥ 80 | 948 | 14.9 ± 2.9 | 490 | 14.7 ± 2.9 | 458 | 15.0 ± 2.8 | |||
Biochemical | |||||||||
Serum total cholesterol (mg/dL) | |||||||||
< 200 | 883 | 14.7 ± 2.9 | 0.30 | 511 | 14.6 ± 2.9 | 0.95 | 372 | 14.9 ± 2.8 | 0.36 |
≥ 200 | 493 | 14.9 ± 2.8 | 219 | 14.6 ± 2.8 | 274 | 15.2 ± 2.8 | |||
Serum high density lipoproteins (mg/dL) | |||||||||
≥ 60 | 1327 | 14.8 ± 2.9 | 0.56 | 715 | 14.6 ± 2.9 | 0.93 | 612 | 15.0 ± 2.8 | 0.72 |
< 60 | 49 | 15.0 ± 2.9 | 15 | 14.7 ± 3.1 | 34 | 15.2 ± 2.8 | |||
Serum triglycerides (mg/dL) | |||||||||
< 150 | 848 | 14.7 ± 2.9 | 0.37 | 448 | 14.5 ± 2.9 | 0.56 | 400 | 14.9 ± 2.7 | 0.46 |
≥150 | 528 | 14.9 ± 2.9 | 282 | 14.7 ± 2.9 | 246 | 15.1 ± 2.9 | |||
HbA1c (%) | |||||||||
Normal (< 5.6) | 97 | 14.7 ± 2.9 | 0.31 | 49 | 14.9 ± 3.1 | 0.72 | 48 | 14.5 ± 2.8 | 0.06 |
Good to Fair (5.6 - 8.0) | 654 | 14.7 ± 2.8 | 346 | 14.5 ± 2.9 | 308 | 14.8 ± 2.7 | |||
Poor (≥ 8.1) | 626 | 14.9 ± 2.9 | 336 | 14.6 ± 2.9 | 290 | 15.3 ± 2.9 | |||
Albuminuria | |||||||||
No micro / macroalbuminuria | 1123 | 14.8 ± 2.8 | 0.43 | 594 | 14.6 ± 2.9 | 0.96 | 529 | 14.9 ± 2.7 | 0.09 |
Microalbuminuria | 217 | 15.0 ± 3.1 | 115 | 14.5 ± 3.2 | 102 | 15.6 ± 2.9 | |||
Macroalbuminuria | 37 | 14.5 ± 2.7 | 22 | 14.5 ± 2.9 | 15 | 14.5 ± 2.6 | |||
FBS (mg/dL) | |||||||||
< 126 | 402 | 14.8 ± 2.9 | 0.85 | 226 | 14.6 ± 3.1 | 0.94 | 176 | 15.0 ± 2.6 | 0.97 |
≥ 126 | 975 | 14.8 ± 2.9 | 505 | 14.6 ± 2.9 | 470 | 15.0 ± 2.9 | |||
CCT (microns) | |||||||||
< 511 | 466 | 14.5 ± 2.8 | 0.002 | 233 | 14.3 ± 2.9 | 0.07 | 233 | 14.6 ± 2.7 | 0.004 |
≥ 511 | 911 | 14.9 ± 2.9 | 498 | 14.7 ± 2.9 | 413 | 15.3 ± 2.8 | |||
Pulse (Beats/min) | |||||||||
< 80 | 960 | 14.6 ± 2.9 | < 0.0001 | 529 | 14.4 ± 2.9 | 0.003 | 431 | 14.9 ± 2.8 | 0.06 |
≥ 80 | 417 | 15.2 ± 2.8 | 202 | 15.1 ± 2.8 | 215 | 15.3 ± 2.8 | |||
Diabetes complications | |||||||||
Diabetic retinopathy | |||||||||
Absent | 1130 | 14.8 ± 2.8 | 0.44 | 578 | 14.6 ± 2.9 | 0.39 | 554 | 15.0 ± 2.7 | 0.77 |
Present | 247 | 14.7 ± 3.1 | 155 | 14.2 ± 3.1 | 92 | 15.1 ± 3.1 | |||
STDR | |||||||||
Absent | 1333 | 14.8 ± 2.9 | 0.54 | 702 | 14.6 ± 2.9 | 0.23 | 631 | 15.0 ± 2.7 | 0.38 |
Present | 44 | 14.5 ± 3.1 | 29 | 13.9 ± 2.9 | 15 | 15.7 ± 3.2 | |||
CSME | |||||||||
Absent | 1361 | 14.8 ± 2.9 | 0.29 | 722 | 14.6 ± 2.9 | 0.62 | 639 | 15.0 ± 2.8 | 0.02 |
Present | 16 | 15.7 ± 3.1 | 9 | 14.1 ± 3.0 | 7 | 17.4 ± 2.2 | |||
Diabetic neuropathy | |||||||||
Absent | 1113 | 14.9 ± 2.8 | 0.008 | 581 | 14.7 ± 2.9 | 0.06 | 532 | 15.1 ± 2.8 | 0.09 |
Present | 251 | 14.4 ± 2.9 | 146 | 14.2 ± 2.9 | 105 | 14.6 ± 2.9 |
Variable | r | p |
---|---|---|
Over All | ||
Age (y) | -0.015 | 0.29 |
Duration of diabetes (y) | -0.035 | 0.09 |
Weight (Kg) | -0.012 | 0.33 |
Height (cm) | -0.012 | 0.004 |
Systolic BP (mmHg) | 0.061 | 0.01 |
Diastolic BP (mmHg) | 0.041 | 0.06 |
Pulse (Beats/min) | 0.074 | 0.003 |
CCT (μ) | 0.139 | <0.001 |
Axial Length (mm) | 0.026 | 0.16 |
Serum Total cholesterol (mg/dL) | 0.047 | 0.04 |
Serum high density lipoproteins (mg/dL) | 0.003 | 0.45 |
Serum Triglycerides (mg/dL) | 0.021 | 0.16 |
HbA1C (%) | 0.035 | 0.10 |
FBS (mg/dL) | 0.045 | 0.04 |
Men | ||
Age (y) | 0.014 | 0.35 |
Duration of diabetes (y) | -0.061 | 0.05 |
Weight (Kg) | -0.011 | 0.38 |
Height (cm) | -0.029 | 0.215 |
Systolic BP (mmHg) | 0.076 | 0.02 |
Diastolic BP (mmHg) | 0.057 | 0.06 |
Pulse (Beats/min) | 0.076 | 0.02 |
CCT (μ) | 0.12 | 0.00 |
Axial length (mm) | 0.057 | 0.06 |
Serum total cholesterol (mg/dL) | 0.013 | 0.36 |
Serum high density lipoproteins (mg/dL) | -0.008 | 0.41 |
Serum triglycerides (mg/dL) | 0.027 | 0.23 |
HbA1C (%) | -0.003 | 0.47 |
FBS (mg/dL) | 0.047 | 0.10 |
Women | ||
Age (y) | -0.041 | 0.14 |
Duration of diabetes (y) | 0.025 | 0.26 |
Weight (kg) | 0.016 | 0.34 |
Height (cm) | -0.027 | 0.24 |
Systolic BP (mmHg) | 0.029 | 0.23 |
Diastolic BP (mmHg) | 0.015 | 0.35 |
Pulse (Beats/min) | 0.058 | 0.01 |
CCT (μ) | 0.182 | <0.001 |
Axial length (mm) | 0.018 | 0.33 |
Serum total cholesterol (mg/dL) | 0.063 | 0.05 |
Serum high density lipoproteins (mg/dL) | -0.008 | 0.41 |
Serum triglycerides (mg/dL) | 0.037 | 0.17 |
HbA1C (%) | 0.08 | 0.02 |
FBS (mg/dL) | 0.039 | 0.16 |
Risk factors | Unadjusted |
||||
---|---|---|---|---|---|
β | 95% CI |
SE | p | ||
Lower bound | Upper bound | ||||
Over All | |||||
Age (y) | -0.004 | -0.02 | 0.011 | 0.008 | 0.58 |
Duration of diabetes (y) | -0.016 | -0.041 | 0.008 | 0.013 | 0.19 |
Weight (Kg) | -0.003 | -0.017 | 0.011 | 0.007 | 0.66 |
Height (cm) | -0.024 | -0.041 | -0.006 | 0.009 | 0.008 |
Systolic BP (mmHg) | 0.008 | 0.001 | 0.016 | 0.004 | 0.02 |
Diastolic BP (mmHg) | 0.01 | -0.003 | 0.024 | 0.007 | 0.13 |
Pulse (Beats/min) | 0.019 | 0.005 | 0.033 | 0.007 | 0.006 |
CCT (μ) | 0.011 | 0.007 | 0.016 | 0.002 | <0.0001 |
Axial length (mm) | 0.061 | -0.062 | 0.183 | 0.063 | 0.33 |
Serum total cholesterol (mg/dL) | 0.003 | 0.000 | 0.007 | 0.002 | 0.08 |
Serum high density lipoproteins (mg/dL) | 0.001 | -0.014 | 0.016 | 0.008 | 0.91 |
Serum triglycerides (mmg/dL) | 0.001 | -0.001 | 0.002 | 0.001 | 0.32 |
HbA1C (%) | 0.045 | -0.024 | 0.115 | 0.035 | 0.20 |
FBS (mg/dL) | 0.002 | 0.000 | 0.005 | 0.045 | 0.09 |
Men | |||||
Age (y) | 0.004 | -0.016 | 0.024 | 0.01 | 0.70 |
Duration of diabetes (y) | -0.027 | -0.058 | 0.005 | 0.016 | 0.10 |
Weight (Kg) | -0.003 | -0.023 | 0.017 | 0.01 | 0.77 |
Height (cm) | -0.013 | -0.044 | 0.019 | 0.016 | 0.43 |
Systolic BP (mmHg) | 0.011 | 0.001 | 0.022 | 0.005 | 0.04 |
Diastolic BP (mmHg) | 0.015 | -0.004 | 0.034 | 0.01 | 0.12 |
Pulse (Beats/min) | 0.021 | 0.001 | 0.041 | 0.01 | 0.04 |
CCT (μ) | 0.01 | 0.004 | 0.016 | 0.003 | 0.001 |
Axial length (mm) | 0.131 | -0.038 | 0.299 | 0.086 | 0.12 |
Serum total cholesterol (mg/dL) | 0.001 | -0.005 | 0.007 | 0.003 | 0.73 |
Serum high density lipoproteins (mg/dL) | -0.003 | -0.025 | 0.02 | 0.011 | 0.82 |
Serum triglycerides (mg/dL) | 0.001 | -0.001 | 0.003 | 0.001 | 0.46 |
HbA1C (%) | -0.004 | -0.102 | 0.094 | 0.05 | 0.99 |
FBS (mg/dL) | 0.002 | -0.001 | 0.006 | 0.047 | 0.20 |
Women | |||||
Age (y) | -0.012 | -0.035 | 0.011 | 0.012 | 0.29 |
Duration of diabetes (in years) | 0.013 | -0.027 | 0.053 | 0.02 | 0.53 |
Weight (kg) | 0.004 | -0.015 | 0.023 | 0.01 | 0.68 |
Height (cm) | -0.013 | -0.049 | 0.023 | 0.018 | 0.49 |
Systolic BP (mmHg) | 0.004 | -0.006 | 0.014 | 0.005 | 0.47 |
Diastolic BP (mmHg) | 0.004 | -0.015 | 0.022 | 0.009 | 0.70 |
Pulse (Beats/min) | 0.014 | -0.005 | 0.032 | 0.009 | 0.14 |
CCT (μ) | 0.015 | 0.009 | 0.021 | 0.003 | <0.0001 |
Axial length (mm) | 0.041 | -0.142 | 0.224 | 0.093 | 0.66 |
Serum total cholesterol (mg/dL) | 0.004 | -0.001 | 0.009 | 0.003 | 0.11 |
Serum high density lipoproteins (mg/dL) | -0.005 | -0.026 | 0.016 | 0.011 | 0.63 |
Serum triglycerides (mg/dL) | 0.001 | -0.001 | 0.004 | 0.001 | 0.35 |
HbA1C (%) | 0.1 | 0.003 | 0.197 | 0.049 | 0.04 |
FBS (mg/dL) | 0.002 | -0.002 | 0.005 | 0.002 | 0.78 |
Risk factors | Adjusted |
p | ||||
---|---|---|---|---|---|---|
Coefficient (β) | 95% CI |
Standard error | Partial r2 | |||
Lower bound | Upper bound | |||||
Over All | ||||||
Height (cm) | -0.028 | -0.048 | -0.007 | 0.01 | 0.005 | 0.007 |
Pulse (Beats/min) | 0.015 | 0.001 | 0.029 | 0.007 | 0.003 | 0.03 |
CCT (μ) | 0.011 | 0.007 | 0.016 | 0.002 | 0.018 | <0.001 |
Model r2 | 0.037 | <0.001 | ||||
Men | ||||||
CCT (μ) | 0.01 | 0.004 | 0.016 | 0.003 | 0.014 | 0.002 |
Model r2 | 0.035 | <0.02 | ||||
Women | ||||||
CCT (μ) | 0.015 | 0.008 | 0.021 | 0.003 | 0.031 | <0.001 |
Model r2 | 0.052 | 0.002 |
GAT: goldmann applanation tonometry, IOP: intraocular pressure, SD: standard deviation.
STDR: sight threatening diabetic retinopathy (severe Nonproliferative diabetic retinopathy, proliferative diabetic retinopathy and clinically significant macular edema), CSME: clinically significant macular edema, HbA1c: glycosylated hemoglobin, BP: blood pressure, CCT: central corneal thickness, BMI: body mass index, FBS: fasting blood sugar.
BP: blood pressure, CCT: central corneal thickness, HbA1c: glycosylated hemoglobin, FBS: fasting blood sugar.
CCT: central corneal thickness, HbA1c: glycosylated hemoglobin, FBS: fasting blood sugar, CI: confidence interval, SE: standard error, SN-DREAMS 1: Sankara Nethralaya-diabetic Retinopathy Epidemiology and Molecular Genetic Study.
CCT: central corneal thickness, CI: confidence interval, SN-DREAMS 1: Sankara Nethralaya-diabetic Retinopathy Epidemiology and Molecular Genetic Study. The variables adjusted in multiple regression analysis are age, duration of diabetes, weight, height, systolic and diastolic blood pressure, pulse, central corneal thickness, axial length, total serum cholesterol, serum high density lipoproteins, serum triglycerides, glycosylated hemoglobin and fasting blood sugar.